Cite

    Castro, M. et al. (2015). Mismatch repair deficiency associated with complete remission to combination programmed cell death ligand immune therapy in a patient with sporadic urothelial carcinoma: immunotheranostic considerations. Journal for immunotherapy of cancer. 3 (1), pp. 1-6. [Online].